Janney Montgomery Scott LLC Cuts Position in Novo Nordisk A/S (NYSE:NVO)

Janney Montgomery Scott LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 26.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,184 shares of the company’s stock after selling 69,383 shares during the period. Janney Montgomery Scott LLC’s holdings in Novo Nordisk A/S were worth $16,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the third quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S during the third quarter valued at approximately $42,000. Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Finally, Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 8.4 %

Shares of NYSE NVO opened at $87.94 on Friday. The stock has a 50 day moving average price of $95.35 and a 200 day moving average price of $115.17. The firm has a market capitalization of $394.65 billion, a price-to-earnings ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.